Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Development Status

Other

121,663

Possibly Marketed Outside US

12,951

Investigational

12,823

US Approved Rx

4,326

US Previously Marketed

2,847

All Match

Any Match

Exclude Selected

Exclude Selected

Primary Target

Histamine H1 receptor

315

Dopamine D2 receptor

297

DNA

278

Bacterial penicillin-binding protein

233

Serotonin 2a (5-HT2a) receptor

231

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Approved

8,429

Phase II

1,132

Phase III

656

Not Provided

504

Phase I

428

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

Unknown

139,593

1921

1,467

2020

742

2013

596

2012

595

All Match

Any Match

Exclude Selected

Exclude Selected

Condition

Unknown

2,578

Pain

614

Cancer

592

Hypertension

567

Breast cancer

434

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Primary

9,569

Curative

2,057

Palliative

1,800

Preventing

1,463

Diagnostic

812

All Match

Any Match

Exclude Selected

Exclude Selected

CNS Activity

CNS Active

3,913

CNS Penetrant

2,554

CNS Non-penetrant

1,014

All Match

Any Match

Exclude Selected

Exclude Selected

Originator

Pfizer

420

Eli Lilly

237

Merck

216

GlaxoSmithKline

193

Novartis

173

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Chemical

111,019

Structurally Diverse

27,047

Protein

6,839

Concept

5,871

Mixture

2,929

All Match

Any Match

Exclude Selected

Exclude Selected

INN Stem

Chemical substance(-ine)

330

Monoclonal antibodies(-mab)

199

Tyrosine-kinase inhibitors(-tinib)

71

Peptides and glycopeptides(-tide)

70

Gene Therapy vectors(-vec)

66

All Match

Any Match

Exclude Selected

Exclude Selected

GInAS Tag

KEW

3,301

84371-57-3

1

ATN-3

1

PUBLIC DOMAIN RELEASE

1

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

FDA UNII

150,149

CAS

113,367

PUBCHEM

108,633

EPA CompTox

76,643

ECHA (EC/EINECS)

33,448

All Match

Any Match

Exclude Selected

Exclude Selected

Protein Type

PEPTIDE

917

MONOCLONAL ANTIBODY

901

ENZYME

484

RECEPTOR

369

MONOCLONAL ANTIBODY CONJUGATE

135

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 1

NERVOUS SYSTEM

528

ALIMENTARY TRACT AND METABOLISM

511

CARDIOVASCULAR SYSTEM

416

ANTIINFECTIVES FOR SYSTEMIC USE

405

ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS

353

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 2

ANTIBACTERIALS FOR SYSTEMIC USE

250

ANTINEOPLASTIC AGENTS

217

OPHTHALMOLOGICALS

198

PSYCHOLEPTICS

172

CARDIAC THERAPY

124

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 3

OTHER ANTINEOPLASTIC AGENTS

139

DIRECT ACTING ANTIVIRALS

88

ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS

76

ANTITHROMBOTIC AGENTS

76

OTHER BETA-LACTAM ANTIBACTERIALS

73

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 4

Antibiotics

52

Other antineoplastic agents

48

Protein kinase inhibitors

47

Enzymes

39

Benzodiazepine derivatives

38

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Principal Form

132,111

Salts, Hydrates, Esters, etc.

18,037

All Match

Any Match

Exclude Selected

Exclude Selected

Showing 156821 - 156828 of 156,828 results

First page
Previous page
15683
Next page disabled
Next page disabled

PHENTERMINE RESIN COMPLEX

C045TQL4WP

Status:

Other

Class:

CONCEPT

BUPIVACAINE LIPOSOME

Y8335394RO

Status:

Other

Class:

CONCEPT

VINCRISTINE SULFATE LIPOSOME

T5IRO3534A

Status:

Other

Class:

CONCEPT

HYDROCODONE RESIN COMPLEX

6YKS4Y3WQ7

Status:

Other

Class:

CONCEPT

HYDROCODONE POLISTIREX

6YKS4Y3WQ7

Status:

Other

Class:

CONCEPT

PHENOL, LIQUEFIED

339NCG44TV

Status:

Other

Class:

CONCEPT

PENTAPEPTIDE-34 TRIFLUOROACETATE

SQS1FA1FGW

Status:

Possibly Marketed Outside US

First approved in 2023

Class:

CONCEPT

REGN-10989

0GFE6DO8AY

Status:

Possibly Marketed Outside US

First approved in 2020

Class:

CONCEPT

Showing 156821 - 156828 of 156,828 results

First page
Previous page
15683
Next page disabled
Next page disabled

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1